Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
21 evidence topics · 14 sources
Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b)
“Similar results were observed for the participants comprising the AChR autoantibody-positive population, with significantly more MGC responders in the Descartes-08 group than in the placebo group (63.6% versus 12.5%, P = 0.025815; Extended Data Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (s.d.) change from baseline in the MGC score at month 3 for those who were AChR autoantibody-positive was −5.0 (5.62) for the Descartes-08 group and 0.1 (4.85) for those treated with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minimum improvements in MGC and MG-ADL scores were higher for the Descartes-08 group than the placebo group at month 3 (Fig. 3), with 81.8% versus 37.5% of participants achieving a minimum of a 3-point improvement in the MGC score and 63.6% versus 25.0% of participants achieving a minimum of a 3-point reduction in the MG-ADL score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: AChR antibody-positive subgroup, MG-ADL change at month 3 and through month 12 (phase 2b)
“There was a significant and clinically meaningful reduction in the mean (s.d.) MG-ADL score at month 3 for the Descartes-08 group compared to the placebo group (−3.4 (2.84) versus 0.6 (2.93), P = 0.0409) (Extended Data Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This reduction in the MG-ADL score was maintained up to month 12 for those in the Descartes-08 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: AChR antibody status as a marker of response (phase 2b)
“Similar trends in MGC response were observed between the overall cohort and the AChR autoantibody-positive population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, these results confirm that, while anti-AChR antibody status is useful in classifying disease, its relevance as a marker to track progression or response to treatment is limited” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In line with this limitation, anti-AChR antibody titer did not correlate with change in clinical disease, as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale (n = 21) (Fig. 3l and Extended Data Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b)
“A post hoc analysis was conducted to evaluate the magnitude of response to Descartes-08 in participants who were biologic-naive and those with prior biologic exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with no prior exposure to complement inhibitors, FcRn inhibitors or CD19/CD20-targeting monoclonal antibodies (biologic-naive) demonstrated an improved response to Descartes-08 compared to those with prior biologic exposure, with 55.6% (n = 5/9) of participants achieving MSE by month 6, which was maintained through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, the biologic-naive group had a greater proportion of MGC responders at month 3 compared to the group with prior biologic exposure (88.9% versus 33.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were also notable reductions in MG severity scores from baseline to month 3 for the biologic-naive group versus those with prior biologic exposure (mean (s.d.) score: MGC −7.7 (5.24) versus 1.0 (6.96); MG-ADL −5.2 (3.27) versus −2.5 (3.08); QMG −5.0 (3.84) versus −2.2 (4.92)), with scores further improved by month 12 (MGC −11.0 (4.0), MG-ADL −7.1 (1.9), QMG −9.4 (2.6)) (Extended Data Table 5 and Extended Data Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, 100.0% of biologic-naive participants maintained at least a clinically meaningful response at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biologic-exposed participants were non-responders to prior FcRn or complement inhibitor treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: authors' interpretation of the biologic-exposure difference (phase 2b)
“There was a notable difference in response between participants who had prior treatment with—and poor response to—complement and FcRn inhibitors and those who were biologic-naive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This may represent a true difference in biology due to a yet-to-be-determined mechanism, an artifact of a small sample size or a reflection of more treatment-refractory disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, it is notable that, even in the cohort of patients who were nonresponders to biologics, a proportion achieved a clinically meaningful improvement in the MGC score after Descartes-08, in contrast to those who were randomized to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: biologic-naive participants with follow-up beyond month 3 (7 participants), company release, April 2025
Descartes-08: early-onset versus late-onset disease, prespecified analysis, mITT population (phase 2b)
“In a prespecified analysis stratifying participants by disease onset, 80.0% (n = 4/5) of those treated with Descartes-08 who had early-onset MG, defined as the development of symptoms before the age of 50 years, were MGC responders at month 3, compared to 20.0% (n = 1/5) in the placebo group (Extended Data Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in MG severity were generally consistent between participants with early-onset MG and those with late-onset MG who were treated with Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: triple seronegative participants and the placebo response (phase 2b)
“The most pronounced improvements in MG severity scales in the placebo group—including one case of MSE—were observed in participants with triple seronegative MG, consistent with larger placebo-controlled studies that included this cohort of patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: postinfusion fever and response, mITT population (phase 2b)
“There were no notable differences in demographics or disease characteristics among participants randomized to Descartes-08 who developed a fever.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, those who developed a fever may have been more likely to respond and experience more pronounced symptom improvement, as measured by the MG-ADL score, than those who did not (Extended Data Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: cell dose and MGC response, post hoc analysis (phase 2b)
“A second post hoc analysis was conducted to assess cell dose infusion and MGC response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the mean cell dose per infusion was similar among those treated with Descartes-08, irrespective of whether they achieved a response or not (Extended Data Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: response across MG types and severity, phase 1b/2a long-term follow-up
MuSK antibody-positive disease: response to conventional therapies
“Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MuSK-MG responds well to PLEX, while IVIg seems to be less effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MuSK antibody-positive disease: complement independence and thymectomy
“The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab response by antibody status
“A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seronegative disease: efgartigimod in anti-AChR antibody-negative adults
Antibody subgroups enrolled in FcRn blocker trials
Potential confounding of network meta-analysis treatment effects by age and sex
“Sensitivity analyses detected potential confounding of treatment effects by age and sex.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings also highlight how differences between trial populations may confound the interpretation of study outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Delayed response to C5 inhibition in therapy-refractory patients: German-Austrian expert guidance
“A clinical response is generally observed within the first 4 weeks after treatment initiation. In patients who do not achieve clinically meaningful improvement within 12 weeks, the decision to continue treatment or switch to an alternative therapy should be individualised [15, 17, 18, 20], as long‐term observational data from non‐placebo‐controlled studies suggest that delayed responses may occur, particularly in therapy‐refractory gMG patients treated with eculizumab or ravulizumab for several months or longer [39, 40].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote